These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30931853)

  • 21. Potential biomarker of fibroblast growth factor 21 in valproic acid-treated livers.
    Xu X; Guo C; Liang X; Li R; Chen J
    Biofactors; 2019 Sep; 45(5):740-749. PubMed ID: 31120577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Children versus adults: pharmacokinetic and adverse-effect differences.
    Anderson GD
    Epilepsia; 2002; 43 Suppl 3():53-9. PubMed ID: 12060006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thinking out of the box: management of valproic acid toxicity with carbapenems.
    Sanivarapu R; Sharma R; Akella J
    BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33692057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver.
    Lee MH; Kim M; Lee BH; Kim JH; Kang KS; Kim HL; Yoon BI; Chung H; Kong G; Lee MO
    Toxicol Appl Pharmacol; 2008 Feb; 226(3):271-84. PubMed ID: 17963808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003.
    Koenig SA; Buesing D; Longin E; Oehring R; Häussermann P; Kluger G; Lindmayer F; Hanusch R; Degen I; Kuhn H; Samii K; Jungck A; Brückner R; Seitz R; Boxtermann W; Weber Y; Knapp R; Richard HH; Weidner B; Kasper JM; Haensch CA; Fitzek S; Hartmann M; Borusiak P; Müller-Deile A; Degenhardt V; Korenke GC; Hoppen T; Specht U; Gerstner T
    Epilepsia; 2006 Dec; 47(12):2027-31. PubMed ID: 17201699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trimetazidine potentiates the antiepileptic activity and ameliorates the metabolic changes associated with pentylenetetrazole kindling in rats treated with valproic acid.
    Sedky AA; El Serafy OMH; Hassan OA; Abdel-Kawy HS; Hasanin AH; Raafat MH
    Can J Physiol Pharmacol; 2017 Jun; 95(6):686-696. PubMed ID: 28177664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation.
    Schiavo A; Maldonado C; Vázquez M; Fagiolino P; Trocóniz IF; Ibarra M
    Eur J Pharm Sci; 2023 Apr; 183():106399. PubMed ID: 36740101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Valproate-associated hepatotoxicity--pathogenesis, clinical aspects, therapy and prevention].
    Siemes H; Nau H
    Klin Padiatr; 1991; 203(6):411-9. PubMed ID: 1758143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity.
    Siemes H; Nau H; Schultze K; Wittfoht W; Drews E; Penzien J; Seidel U
    Epilepsia; 1993; 34(2):332-46. PubMed ID: 8453944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of valproic acid on the expression of various acyl-CoA dehydrogenases in rats.
    Kibayashi M; Nagao M; Chiba S
    Pediatr Int; 1999 Feb; 41(1):52-60. PubMed ID: 10200137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatotoxicity in rat following administration of valproic acid.
    Sugimoto T; Woo M; Nishida N; Takeuchi T; Sakane Y; Kobayashi Y
    Epilepsia; 1987; 28(2):142-6. PubMed ID: 3102219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective effects of naringin on valproic acid-induced hepatotoxicity in rats.
    Koroglu OF; Gunata M; Vardi N; Yildiz A; Ates B; Colak C; Tanriverdi LH; Parlakpinar H
    Tissue Cell; 2021 Oct; 72():101526. PubMed ID: 33756270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum carnitine during valproic acid therapy.
    Laub MC; Paetzke-Brunner I; Jaeger G
    Epilepsia; 1986; 27(5):559-62. PubMed ID: 3093213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.
    Wang C; Wang P; Yang LP; Pan J; Yang X; Ma HY
    Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?
    Lheureux PE; Penaloza A; Zahir S; Gris M
    Crit Care; 2005 Oct; 9(5):431-40. PubMed ID: 16277730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease in adolescents receiving valproic acid.
    Verrotti A; Agostinelli S; Parisi P; Chiarelli F; Coppola G
    Epilepsy Behav; 2011 Feb; 20(2):382-5. PubMed ID: 21256090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between the perturbation of bile acid homeostasis and valproic acid-induced hepatotoxicity.
    Chen Y; Zhou J; Xu S; Liu M; Wang M; Ma Y; Zhao M; Wang Z; Guo Y; Zhao L
    Biochem Pharmacol; 2019 Dec; 170():113669. PubMed ID: 31628911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
    Saneto RP; Lee IC; Koenig MK; Bao X; Weng SW; Naviaux RK; Wong LJ
    Seizure; 2010 Apr; 19(3):140-6. PubMed ID: 20138553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valproic acid hepatic fatalities. III. U.S. experience since 1986.
    Bryant AE; Dreifuss FE
    Neurology; 1996 Feb; 46(2):465-9. PubMed ID: 8614514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: the controversy.
    Wyllie E; Wyllie R
    Epilepsia; 1991; 32 Suppl 5():S74-9. PubMed ID: 1743173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.